Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
12
DRMA Quote, Financials, Valuation and Earnings
Last price:
$2.16
Seasonality move
:
-34.61%
Day range:
$2.25 - $2.42
52-week range:
$2.21 - $23.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.60x
Volume:
66.3K
Avg. volume:
158.5K
1-year change:
-79.09%
Market cap:
$2.4M
Revenue:
--
EPS (TTM):
-$16.27
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DRMA
Dermata Therapeutics, Inc.
|
-- | -- | -- | -- | $10.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DRMA
Dermata Therapeutics, Inc.
|
$2.30 | $10.00 | $2.4M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3.50 | $0.85 | $441M | 5.88x | $0.80 | 0% | 6.80x |
|
NNVC
NanoViricides, Inc.
|
$1.24 | $6.50 | $22.3M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.82 | $2.00 | $678.8K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.18 | $7.00 | $6.2M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DRMA
Dermata Therapeutics, Inc.
|
-- | -1.540 | -- | 4.20x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DRMA
Dermata Therapeutics, Inc.
|
-- | -$1.8M | -190.86% | -190.86% | -- | -$1.8M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Dermata Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns DRMA or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Dermata Therapeutics, Inc.'s net margin of -255.85%. Dermata Therapeutics, Inc.'s return on equity of -190.86% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital DRMADermata Therapeutics, Inc.-- -$1.65 $4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About DRMA or NBY?
Dermata Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 334.78%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -75.71%. Given that Dermata Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Dermata Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRMADermata Therapeutics, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is DRMA or NBY More Risky?
Dermata Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock DRMA or NBY?
Dermata Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Dermata Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRMA or NBY?
Dermata Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Dermata Therapeutics, Inc.'s net income of -$1.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Dermata Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 5.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dermata Therapeutics, Inc. is -- versus 6.80x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRMADermata Therapeutics, Inc.-- -- -- -$1.7M NBYNovaBay Pharmaceuticals, Inc.6.80x 5.88x $521K -$1.3M
-
Which has Higher Returns DRMA or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Dermata Therapeutics, Inc.'s net margin of --. Dermata Therapeutics, Inc.'s return on equity of -190.86% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital DRMADermata Therapeutics, Inc.-- -$1.65 $4M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About DRMA or NNVC?
Dermata Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 334.78%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 424.19%. Given that NanoViricides, Inc. has higher upside potential than Dermata Therapeutics, Inc., analysts believe NanoViricides, Inc. is more attractive than Dermata Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRMADermata Therapeutics, Inc.0 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is DRMA or NNVC More Risky?
Dermata Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock DRMA or NNVC?
Dermata Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dermata Therapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRMA or NNVC?
Dermata Therapeutics, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Dermata Therapeutics, Inc.'s net income of -$1.7M is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, Dermata Therapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dermata Therapeutics, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRMADermata Therapeutics, Inc.-- -- -- -$1.7M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns DRMA or OGEN?
Oragenics, Inc. has a net margin of -- compared to Dermata Therapeutics, Inc.'s net margin of --. Dermata Therapeutics, Inc.'s return on equity of -190.86% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital DRMADermata Therapeutics, Inc.-- -$1.65 $4M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About DRMA or OGEN?
Dermata Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 334.78%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 142.45%. Given that Dermata Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Dermata Therapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRMADermata Therapeutics, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is DRMA or OGEN More Risky?
Dermata Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock DRMA or OGEN?
Dermata Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dermata Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRMA or OGEN?
Dermata Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Dermata Therapeutics, Inc.'s net income of -$1.7M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Dermata Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dermata Therapeutics, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRMADermata Therapeutics, Inc.-- -- -- -$1.7M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns DRMA or PTN?
Palatin Technologies has a net margin of -- compared to Dermata Therapeutics, Inc.'s net margin of --. Dermata Therapeutics, Inc.'s return on equity of -190.86% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRMADermata Therapeutics, Inc.-- -$1.65 $4M PTNPalatin Technologies-- -- -- -
What do Analysts Say About DRMA or PTN?
Dermata Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 334.78%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Dermata Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Dermata Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRMADermata Therapeutics, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is DRMA or PTN More Risky?
Dermata Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock DRMA or PTN?
Dermata Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dermata Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRMA or PTN?
Dermata Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Dermata Therapeutics, Inc.'s net income of -$1.7M is higher than Palatin Technologies's net income of --. Notably, Dermata Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dermata Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRMADermata Therapeutics, Inc.-- -- -- -$1.7M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns DRMA or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Dermata Therapeutics, Inc.'s net margin of --. Dermata Therapeutics, Inc.'s return on equity of -190.86% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital DRMADermata Therapeutics, Inc.-- -$1.65 $4M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About DRMA or TOVX?
Dermata Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 334.78%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3716.79%. Given that Theriva Biologics, Inc. has higher upside potential than Dermata Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Dermata Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRMADermata Therapeutics, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is DRMA or TOVX More Risky?
Dermata Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock DRMA or TOVX?
Dermata Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dermata Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRMA or TOVX?
Dermata Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Dermata Therapeutics, Inc.'s net income of -$1.7M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Dermata Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dermata Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRMADermata Therapeutics, Inc.-- -- -- -$1.7M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 37x
Alerts
Sell
46
BE alert for Dec 18
Bloom Energy Corp. [BE] is up 4.27% over the past day.
Sell
44
STRL alert for Dec 18
Sterling Infrastructure, Inc. [STRL] is up 6.62% over the past day.
Sell
39
SOXL alert for Dec 18
Direxion Daily Semiconductor Bull 3X Shares [SOXL] is up 7.28% over the past day.
